Worldwide community-acquired pneumonia (CAP) continues to be a leading cause of morbidity and mortality. 1 Streptococcus pneumoniae (S. pneumoniae) and Staphylococcus aureus (S. aureus) including methicillin-sensitive S. aureus (MSSA) are important etiological pathogens. 1 Initial therapy for CAP includes ฮฒ-lactam or ฮฒ-lactam/macrolide antimicrobials. 1 However, antimicrobial resistance among the major pathogens is a cause of concern.
3 Ceftaroline fosamil is a broad-spectrum cephalosporin and has proven efficacy and safety against S. aureus CAP. 1 The present article highlights the general properties of ceftaroline fosamil and its clinical efficacy. The CAP remains a critical healthcare concern despite advancements in antibiotic therapy. 1 Annually, CAP affects around 5โ11 individuals per 1000 population across the world. 2 About 20% of these cases require hospitalization. 2 In India,โฆ
